Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.

[1]  L. Pleyer,et al.  Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group , 2014, Annals of Hematology.

[2]  H. Dombret,et al.  Azacitidine in untreated acute myeloid leukemia: A report on 149 patients , 2014, American journal of hematology.

[3]  E. Vellenga,et al.  Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. , 2013, Leukemia research.

[4]  J. Bennett,et al.  A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial , 2013, Haematologica.

[5]  M. Duchosal,et al.  Transfusion independence and survival in patients with acute myeloid leukemia treated with 5-azacytidine , 2012, Haematologica.

[6]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Levis,et al.  Azacitidine for the treatment of patients with acute myeloid leukemia , 2012, Cancer.

[8]  E. Vellenga,et al.  Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme , 2011, British journal of haematology.

[9]  J. Dipersio,et al.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Dombret,et al.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[12]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[13]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Hills,et al.  A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.

[15]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[16]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[17]  D. Grimwade,et al.  The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.